Home > Haematology > EHA 2022 > Quizartinib prolongs survival of newly diagnosed FLT3-ITD-mutated AML patients

Quizartinib prolongs survival of newly diagnosed FLT3-ITD-mutated AML patients

Presented By
Dr Harry Erba, Duke Cancer Institute, NC, USA
Conference
EHA 2022
Trial
Phase 3, QuANTUM-First
Quizartinib improves overall survival when combined with standard induction and consolidation therapy, and as continuation therapy as a single agent for up to 3 years in patients with newly diagnosed FLT3-ITD-mutated acute myeloid leukaemia (AML), results from the phase 3 QuANTUM-First study demonstrate. FLT3 is among the most common AML mutations, with FLT3-ITD mutations being associated with poor prognosis, high relapse, and inferior overall survival, and the prognosis of FLT3-TKD mutations being unclear [1,2]. The RATIFY study (NCT00651261) showed improved overall survival in FLT3-mutated AML patients with midostaurin, albeit with a high rate of relapse [3]. Quizartinib is a highly potent and selective second-generation type II FLT3 inhibitor that demonstrated a signal of clinical efficacy and a manageable safety pro...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on